Sharp-Header

Sharp-Header

X

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Reset Filter

All Drugs in Dev.

Product Type

Companies

Eligo Bioscience

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Food & Nutrition Conference & Expo

Participation Not Confirmed

Update your Virtual Booth

Eligo Bioscience Inks Deal with GSK Potentially Worth up to $224 Million

Lead Product(s): EB005

Therapeutic Area: Dermatology Product Name: EB005

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: GlaxoSmithKline

Deal Size: $224.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration January 11, 2021

Details:

Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agr